Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial uri icon

abstract

  • BACKGROUND: The achievement of glycaemic control remains challenging for patients with type 1 diabetes. We assessed the effectiveness of day-and-night hybrid closed-loop insulin delivery compared with sensor-augmented pump therapy in people with suboptimally controlled type 1 diabetes aged 6 years and older. METHODS: In this open-label, multicentre, multinational, single-period, parallel randomised controlled trial, participants were recruited from diabetes outpatient clinics at four hospitals in the UK and two centres in the USA. We randomly assigned participants with type 1 diabetes aged 6 years and older treated with insulin pump and with suboptimal glycaemic control (glycated haemoglobin [HbA1c] 7.5-10.0%) to receive either hybrid closed-loop therapy or sensor-augmented pump therapy over 12 weeks of free living. Training on study insulin pump and continuous glucose monitoring took place over a 4-week run-in period. Eligible subjects were randomly assigned using central randomisation software. Allocation to the two study groups was unblinded, and randomisation was stratified within centre by low (<8.5%) or high (>/=8.5%) HbA1c. The primary endpoint was the proportion of time that glucose concentration was within the target range of 3.9-10.0 mmol/L at 12 weeks post randomisation. Analyses of primary outcome and safety measures were done in all randomised patients. The trial is registered with ClinicalTrials.gov, number NCT02523131, and is closed to accrual. FINDINGS: From May 12, 2016, to Nov 17, 2017, 114 individuals were screened, and 86 eligible patients were randomly assigned to receive hybrid closed-loop therapy (n=46) or sensor-augmented pump therapy (n=40; control group). The proportion of time that glucose concentration was within the target range was significantly higher in the closed-loop group (65%, SD 8) compared with the control group (54%, SD 9; mean difference in change 10.8 percentage points, 95% CI 8.2 to 13.5; p<0.0001). In the closed-loop group, HbA1c was reduced from a screening value of 8.3% (SD 0.6) to 8.0% (SD 0.6) after the 4-week run-in, and to 7.4% (SD 0.6) after the 12-week intervention period. In the control group, the HbA1c values were 8.2% (SD 0.5) at screening, 7.8% (SD 0.6) after run-in, and 7.7% (SD 0.5) after intervention; reductions in HbA1c percentages were significantly greater in the closed-loop group compared with the control group (mean difference in change 0.36%, 95% CI 0.19 to 0.53; p<0.0001). The time spent with glucose concentrations below 3.9 mmol/L (mean difference in change -0.83 percentage points, -1.40 to -0.16; p=0.0013) and above 10.0 mmol/L (mean difference in change -10.3 percentage points, -13.2 to -7.5; p<0.0001) was shorter in the closed-loop group than the control group. The coefficient of variation of sensor-measured glucose was not different between interventions (mean difference in change -0.4%, 95% CI -1.4% to 0.7%; p=0.50). Similarly, total daily insulin dose was not different (mean difference in change 0.031 U/kg per day, 95% CI -0.005 to 0.067; p=0.09) and bodyweight did not differ (mean difference in change 0.68 kg, 95% CI -0.34 to 1.69; p=0.19). No severe hypoglycaemia occurred. One diabetic ketoacidosis occurred in the closed-loop group due to infusion set failure. Two participants in each study group had significant hyperglycaemia, and there were 13 other adverse events in the closed-loop group and three in the control group. INTERPRETATION: Hybrid closed-loop insulin delivery improves glucose control while reducing the risk of hypoglycaemia across a wide age range in patients with suboptimally controlled type 1 diabetes. FUNDING: JDRF, NIHR, and Wellcome Trust.

publication date

  • 2018